Basaglar now available for prescription in U.S.
"Lilly and Boehringer Ingelheim are proud to bring another proven effective diabetes treatment choice to people who may need a long-acting insulin to help control their blood sugar," Lilly Diabetes Vice President of Global Medical Affairs Dr. David Kendall said. "We know that starting insulin can be a challenging experience for some people with type 2 diabetes. As part of our continuing commitment to the diabetes community, we are expanding our educational resources."
The FDA previously approved Basaglar in 2015 as a long-acting insulin for controlling high blood pressure.
"In my practice, I regularly see people with type 2 diabetes who feel completely overwhelmed or nervous when they learn they need to begin insulin treatment," AHEC Southern Regional Consulting Associate for Medicine and Community and Family Medicine Dr. Eugene Wright said. "These feelings are understandable because many people with type 2 diabetes face fear and anxiety about injections, a sense of failure about the progression of their condition, or concern over fitting insulin into daily life."
Organizations in this story
Eli Lilly and Company 1555 S Harding St Indianapolis, IN - 46221